Head to head

SLU-PP-332 vs Tesofensine

Metabolic

A comparison decided mostly by evidence: Tesofensine has been studied in people to a degree the other has not.

Verdict

One has been tested in people; the other has not

If your priority is the compound with the strongest published support, that is Tesofensine. SLU-PP-332 is not therefore worse — it is less examined, which is a different thing — but the gap is the single most defensible difference on this page, and it is the one most comparisons quietly skip.

What you are actually choosing between

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — SLU-PP-332 rates 4/5 for fat loss and Tesofensine rates 4/5. Outside that overlap they diverge: SLU-PP-332 also carries weight for metabolic health, Tesofensine for appetite control.

The evidence

This is the part that decides most of it. Tesofensine has approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. SLU-PP-332 has animal and cell data only, and no controlled human dosing trials — there are no human trials of any kind. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

Tesofensine has a characterized half-life of 9.2 days; SLU-PP-332 does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.

Committed time differs: SLU-PP-332 runs 8 weeks, Tesofensine runs 24 weeks.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

SLU-PP-332

A synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), not a peptide. It is marketed as an "exercise mimetic" because in mice it increased oxidative metabolism, running endurance and fat oxidation and reduced fat gain on a high-fat diet without changing food intake. That is the entire evidence base: preclinical rodent and cell work from academic labs. There are NO human trials, no human pharmacokinetics, no human safety data and no published human dosing whatsoever — nothing here is derived from a study in people. It is sold as 1 mg oral tablets, so the 500-1000 mcg (0.5-1 mg) daily range shown is simply half a tablet to one tablet: a deliberately narrow, conservative reading of vendor packaging, not a validated dose. Human half-life is unknown, so it is left null rather than guessed. It is swallowed as tablets rather than reconstituted, so the reconstitution fields do not apply. Treat every number on this page as the lowest possible confidence.

Tesofensine

An oral triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor, not a peptide. A 24-week randomized phase 2 obesity trial tested 0.25, 0.5 and 1.0 mg daily; 0.5 mg is the dose carried forward and the strength approved in Mexico. It is NOT FDA or EMA approved. The 1.0 mg arm produced clearly more cardiovascular and psychiatric adverse effects, so the upper end of this range is documented but not recommended. Values here are capsule strengths in mg, not vial sizes, and the reconstitution fields do not apply to an oral drug.

Side by side

The numbers

SLU-PP-332 compared with Tesofensine
Attribute	SLU-PP-332	Tesofensine
Class	Metabolic	Metabolic
Routes	Oral	Oral
Dose range	500 mcg–1 mg (typical 1 mg)	250 mcg–1 mg (typical 500 mcg)
Frequency	Once daily	Once daily
Half-life	Not characterized	9.2 days
Cycle length	8 weeks	24 weeks
Experience	Advanced	Advanced
Evidence	Animal / cell data only	Approved elsewhere
Contraindications	Pregnant / nursing Under 18	Pregnant / nursing Under 18
Side effects	Unknown in humans — no clinical safety data of any kind exists Stimulant-like restlessness or insomnia reported anecdotally, not in any trial Elevated heart rate reported anecdotally Rodent studies used doses far above anything sold to consumers, so the animal safety record does not translate to human tablets	Insomnia, especially when taken late in the day Dry mouth Raised heart rate and blood pressure, dose-dependent and pronounced above 0.5 mg Agitation, anxiety or mood change Nausea and constipation

Goals

Where they overlap, and where they do not

Goal	SLU-PP-332	Tesofensine
fat loss	SLU-PP-332: 4/5	Tesofensine: 4/5
appetite controlone only	SLU-PP-332: —	Tesofensine: 5/5
metabolic healthone only	SLU-PP-332: 4/5	Tesofensine: —
longevityone only	SLU-PP-332: 2/5	Tesofensine: —
muscle growthone only	SLU-PP-332: 2/5	Tesofensine: —

They overlap on 1 goal and diverge on 4. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographSLU-PP-332Mechanism, protocol, storage, sources.MonographTesofensineMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.